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Abstract Aberrant alternative pre-mRNA splicing (AS) events have been associated with several
disorders. However, it is unclear whether deregulated AS directly contributes to disease. Here, we
reveal a critical role of the AS regulator epithelial splicing regulator protein 1 (ESRP1) for intestinal
homeostasis and pathogenesis. In mice, reduced ESRP1 function leads to impaired intestinal barrier
integrity, increased susceptibility to colitis and altered colorectal cancer (CRC) development.
Mechanistically, these defects are produced in part by modified expression of ESRP1-specific
Gpr137 isoforms differently activating the Wnt pathway. In humans, ESRP1 is downregulated in
inflamed biopsies from inflammatory bowel disease patients. ESRP1 loss is an adverse prognostic
factor in CRC. Furthermore, generation of ESRP1-dependent GPR137 isoforms is altered in CRC
and expression of a specific GPR137 isoform predicts CRC patient survival. These findings indicate
a central role of ESRP1-regulated AS for intestinal barrier integrity. Alterations in ESRP1 function or
expression contribute to intestinal pathology.
DOI: https://doi.org/10.7554/eLife.28366.001
Introduction
The single-layered intestinal epithelium provides an important physical barrier that critically contrib-
utes to intestinal homeostasis (Peterson and Artis, 2014). Dysfunction of intestinal epithelial cells
(IECs) leading to increased epithelial permeability is associated with intestinal diseases such as
inflammatory bowel disease (IBD) and colorectal cancer (CRC) (Van der Sluis et al., 2006;
Schmitz et al., 1999; Grivennikov et al., 2012). IBD is related to polymorphisms in various IBD sus-
ceptibility genes (Lees et al., 2011; Van Limbergen et al., 2014), and numerous genetic alterations
in key cellular pathways that underlie CRC have been identified (Fearon, 2011). However, the role
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of post-transcriptional modifications in the regulation of IBD and CRC development is still poorly
understood.
Alternative splicing of pre-mRNAs (AS) is a common posttranscriptional modification that is esti-
mated to occur in 92–94% of human genes (Wang et al., 2008; Pan et al., 2008). AS permits gener-
ation of protein isoforms with related, distinct or sometimes even opposing functions
(Vorlova´ et al., 2011). Moreover, certain isoforms influence cancer progression (Brown et al., 2011)
or are associated with autoimmune and inflammatory disorders (Ueda et al., 2003; Laitinen et al.,
2004). While alterations of mRNA splicing have been reported in human colorectal cancer (CRC)
(Freund et al., 2015; Zhou et al., 2014) and IBD (Ha¨sler et al., 2011; Mailer et al., 2015), the con-
sequences of deregulated AS for intestinal homeostasis and disease development are largely
unexplored.
Epithelial splicing regulatory protein 1 (ESRP1), which is exclusively expressed in epithelial cells,
was identified in a cDNA expression screen for factors that promote the epithelial pattern of FGFR2
(Fibroblast Growth Factor Receptor 2) splicing. ESRP1 was also found to regulate the AS of CD44
and other genes (Warzecha et al., 2009). ESRP1 is negatively regulated by mesenchymal transcrip-
tion factors such as SNAIL, ZEB1 and ZEB2 (Preca et al., 2015; Saitoh, 2015; Reinke et al., 2012).
Recently, ESRP1 has been reported to act as a tumor suppressor by negatively regulating epithelial-
to-mesenchymal transition (EMT) and the metastatic potential of human breast cancer cell lines, via
the splicing of different isoforms of CD44 or EXO70 (Lu et al., 2013). ESRP1 can suppress cancer
cell motility in head and neck carcinoma cell lines (Ishii et al., 2014) and ESRP1 protein expression is
a favorable prognostic factor in pancreatic cancer (Ueda et al., 2014). However, ESRP1 may also
promote lung metastasis of orthotopically transplanted breast cancer cells by generating CD44 iso-
forms independently of EMT (Yae et al., 2012). Yet, the contribution of ESRP1 to intestinal integrity
and function is poorly investigated. Importantly, the lack of viable animal models so far has pre-
cluded analyzing the role of ESRP1-mediated AS for intestinal disease in vivo.
Here, we used a novel mutant allele of Esrp1 called Triaka to investigate the function of ESRP1 in
the intestine. We found that Esrp1Triaka (later referred to as Triaka) leads to reduced ESRP1 function
causing distinct alterations in the mRNA splicing pattern in colonic IECs (cIECs) of Triaka compared
eLife digest The lining of the intestine is just one cell thick, and yet it can act as an effective
barrier between the inside of the body and the contents of the digestive system. This lining is often
disturbed during bowel cancer, inflammatory bowel disease and other intestinal diseases, causing
the barrier to fail and the gut to become leaky. These diseases often reduce patient life expectancy
and quality of life.
Intestinal epithelial cells make up the lining of the intestine and the normal activities of these cells
are often disturbed during intestinal disease. In the intestine, a protein called ESRP1 is only found in
epithelial cells, but its role in maintaining a healthy intestinal lining was not clear. Here, Mager et al.
studied the intestines of mice that had been genetically engineered to produce a form of ESRP1
that is less active than normal.
The experiments show that lower levels of ESRP1 activity leads to a broken intestinal barrier. The
genetically engineered mice were more likely to develop inflammatory bowel disease and more
aggressive forms of cancer. ESRP1 controls a gene that encodes another protein called GPR137,
which helps to relay signals to the epithelial cells. Lower levels of ESRP1 resulted in a longer form of
the GPR137 protein being produced. This in turn affected the protein’s signaling role and disturbed
the activities of intestinal epithelial cells.
Further experiments on biopsies taken from patients with inflammatory bowel disease or
colorectal cancer revealed that these patients had lower levels of ESRP1 compared to healthy
individuals. Furthermore, low levels of ESRP1 and increased levels of the long version of GPR137
were associated with poorer outcomes for cancer patients. Together, these findings may help us to
better understand how the intestinal barrier fails in mice and humans and could lead to new ways to
monitor and treat intestinal disease.
DOI: https://doi.org/10.7554/eLife.28366.002
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with wild-type (WT) animals. These changes in several transcript isoforms do not alter intestinal histo-
morphology, yet they are associated with increased intestinal permeability in Triaka mice. In addi-
tion, Triaka mice show alterations in distinct models of intestinal disease. Mechanistically, this
phenotype can be ascribed, in part, to changes in the relative frequency of specific Gpr137 splicing
isoforms in Triaka cIECs. This affects the survival and function of cIEC by altering the Wnt signaling
pathway in Triaka mice. In humans, ESRP1 transcript levels are downregulated in inflamed compared
with non-inflamed biopsies from IBD patients. Furthermore, ESRP1 expression is gradually lost dur-
ing the adenoma to carcinoma sequence in CRC, and loss of ESRP1 protein expression in CRC
tumors negatively correlates with patient survival. Moreover, the ratio of specific GPR137 isoforms is
different in tumor versus normal intestinal tissue, and expression of a specific ESRP1-dependent
GPR137 isoform predicts CRC patient survival.
Together, these data indicate an important role for ESRP1 in intestinal disease in humans and
mice.
Results
Esrp1Triaka reduces mRNA splicing function
To study the role of ESRP1 in the intestinal epithelium, we used a novel mutant allele of Esrp1 called
Triaka that was identified in an N-ethyl-N-nitrosourea genetic screen. The Triaka point mutation
results in a methionine-to-valine substitution at the amino acid position 161 (M161V) of ESRP1, a res-
idue conserved in several species (Figure 1—figure supplement 1). Triaka animals develop overtly
normal (see also Materials and methods), which allows investigation of the physiological role of
Esrp1 in adults. This is in contrast to the recently published Esrp1-/- or skin epithelial-specific Esrp1-
deficient animals that are neonatal lethal (Bebee et al., 2015). We first utilized a previously
described in vitro reporter system to characterize the effect of Esrp1Triaka on the splicing of known
ESRP1-regulated transcripts (Brown et al., 2011). Using this system based on luciferase expression,
we found that WT ESRP1 protein led to a 2.4 and 10.9 fold increase of Cd44 variable exon v5
(Cd44v5) and Fgfr2 variable exon IIIb (Fgfr2-IIIb) inclusion, respectively, compared to control. This
was in line with earlier reports (Brown et al., 2011; Warzecha et al., 2009). ESRP1Triaka however
showed reduced levels of Cd44v5 and Fgfr2-IIIb inclusion, with 1.8 and 3.3 fold induction, respec-
tively (Figure 1A and B). This variation in the extent of in vitro splicing of Cd44 versus Fgfr2 by
ESRP1Triaka likely related to the fact that Esrp1-regulated splicing events show distinct sensitivity to
Esrp1 loss (Warzecha et al., 2009; Bebee et al., 2015).
We then transduced CMT-93 cells with inducible lentiviral encoding Esrp1WT or Esrp1Triaka to
assess the effect of the mutation on epithelial cell function. At the same level of overexpression as
Esrp1WT, Esrp1Triaka led to diminished inclusion of Cd44v4/5 in CMT-93 cells and reduced cell prolif-
eration (Figure 1C–E). Of note, Esrp1WT transcript levels directly correlated with frequency of
Cd44v4/5 splicing events, suggesting a dose-dependent effect of Esrp1 expression on Esrp1-medi-
ated splicing activity (Figure 1F). Taken together, these in vitro data indicate that Esrp1Triaka reduces
ESRP1 function, and thereby decreases the proliferative capacity of epithelial cells.
Esrp1Triaka leads to altered mRNA splicing pattern in vivo
Esrp1 has been shown to be epithelial cell-restricted and to be highly expressed in the murine large
intestine (Warzecha et al., 2009). Thus, we next investigated the impact of Esrp1Triaka on the mRNA
splicing pattern of cIECs. RNA sequencing was performed on cIECs isolated from naı¨ve mice.
Computational analysis revealed 35 genes for which the relative frequency of splicing isoforms dif-
fered in Esrp1Triaka versus Esrp1WT cIECs (Figure 2A and B, Figure 2—source data 1). These find-
ings were validated using quantitative reverse-transcription polymerase chain reaction (qPCR) for
selected, previously reported ESRP1 target genes, including Cd44 and Magi1 (Brown et al., 2011;
Warzecha et al., 2009; Warzecha et al., 2010), and for novel candidate targets, including Uap1
and Gpr137 (Figure 2C). Functional alterations induced by ESRP1Triaka were also apparent on the
protein level, as expression of CD44 variant 4 (CD44v4)-containing isoforms, but not total CD44, was
reduced in colonic sections of Triaka versus WT mice (Figure 2D and Figure 2—figure supplement
1). Therefore, these results suggested Esrp1Triaka-dependent functional changes in mutant mice.
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Figure 1. Esrp1Triaka leads to altered mRNA splicing and reduced epithelial cell proliferation. To quantify exon splicing, HEK-293 cells were co-
transfected with a vector encoding Esrp1WT or Esrp1Triaka or an empty control (CTRL) vector and with an exon trap construct containing (A) Cd44 variant
5 (Cd44v5) or (B) Ffgr2-IIIb variable exon. Upper panels in (A) and (B) show schemes of the respective exon trap constructs. Inclusion of exon Cd44v5 or
Ffgr2-IIIb results in luciferase (Luc) expression. Luciferase activity normalized to control vector-transfected cells is shown in the lower panels. Relative
expression of (C) Esrp1 and (D) Cd44v4/5 transcripts were measured in CMT-93 cells transduced with inducible vectors encoding Esrp1WT, Esrp1Triaka, or
a control construct, after treatment with 4-hydroxytamoxifen. (E) Proliferation of Esrp1WT- and Esrp1Triaka-expressing CMT-93 cells was measured using a
WST-1 assay and normalized to control vector-transduced cells. (F) Relative expression of Esrp1 and Cd44v4/5 transcripts were measured in CMT-93
cells transduced with a vector encoding Esrp1WT, after induction with 4-hydroxytamoxifen, and correlated. Data represent: Pooled means ± standard
error of the mean from (A and B) five or (C–E) three independent experiments performed in biological triplicates. (F) Means measured in technical
duplicates (n = 22). Statistics: (A–D) One-way ANOVA with Bonferroni post-test. (E) Two-way ANOVA with Bonferroni post-test. (F) Spearman
correlation. **p<0.01; ***p<0.001; ****p<0.0001.
DOI: https://doi.org/10.7554/eLife.28366.003
The following figure supplement is available for figure 1:
Figure supplement 1. Mapping of the Triaka mutation.
DOI: https://doi.org/10.7554/eLife.28366.004
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Figure 2. Esrp1Triaka alters mRNA splicing patterns in colonic intestinal epithelial cells. (A) RNA sequencing analysis was performed on colonic intestinal
epithelial cells (cIECs) isolated from WT and Triaka mice. Dot plot indicating the relative difference in isoform usage for a given transcription start site
expressed as Jensen-Shannon divergence and the associated p-values. Analysis was performed through CummeRbund and FDR-adjusted p-value<0.05
Figure 2 continued on next page
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Esrp1Triaka impairs the integrity of the intestinal barrier
We next compared the gene expression profiling of Triaka versus WT cIECs to assess potential func-
tional effects of Esrp1Triaka. Pathway analysis of the RNA sequencing data showed that several path-
ways involved in cell cycle and proliferation were affected in Triaka cIECs (Figure 3—figure
supplement 1 and Figure 3—source data 1). Yet, these transcriptional changes did not overtly alter
intestinal histomorphology and epithelial proliferation, as crypt depth, number of goblet cells and
Ki-67 expression were similar in Triaka versus WT mice (Figure 3—figure supplement 2A–F). Fur-
thermore, Triaka and WT mice showed similar colon length at steady-state (Figure 3—figure supple-
ment 2G). However, E-cadherin (CDH1) surface expression was reduced on Triaka cIECs (Figure 3A
and B). Given the central role of E-cadherin for epithelial cell function, we hypothesized a possible
defect in intestinal epithelial barrier integrity in Triaka mice. Indeed, ex vivo measurement of the
intestinal electrical resistance indicated an increased ion permeability of Triaka versus WT colonic
mucosa (Figure 3C), although there was no such difference in the small intestine (Figure 3—figure
supplement 3A). This was accompanied by the presence of bacterial 16S rRNA in intestinal crypts
and in the inner mucus layer of Triaka but not WT colons (Figure 3D and Table 1). As further indirect
evidence of reduced barrier integrity, we also detected systemic anti-commensal IgG1 and IgG2b
antibody reactivity towards autologous intestinal bacteria in most Triaka mice, but rarely in control
animals (Figure 3E and Table 1). However, levels of fecal albumin and lipocalin-2 – markers for intes-
tinal lesions and inflammation – were similar in fecal pellets of Triaka and WT mice (Figure 3—figure
supplement 3B and C). Furthermore, there was no difference in the resorption of macromolecules
between Triaka and WT mice (22 ± 1 versus 24 ± 3 mg/ml serum FITC-dextran-4000 levels, respec-
tively, p=0.6).
In summary, these data suggest that reduced Esrp1-dependent mRNA splicing in Triaka animals
results in decreased integrity of the colonic epithelial barrier and intestinal penetration of bacterial
products. These epithelial defects are however not sufficient to induce intestinal immunopathology
in naı¨ve Triaka mice.
Esrp1Triaka modulates intestinal immunopathology
Next, we addressed whether the Esrp1Triaka-dependent alterations observed at steady-state in Triaka
mice may affect intestinal disease. Compared with WT controls, Triaka animals treated with dextran
sodium sulfate (DSS) in drinking water for 7 days, a disease model of intestinal inflammation and
damage, showed increased weight loss and pronounced shortening of the colon (Figure 4A and B).
This was also reflected by higher disease scores, both clinically and histologically (Figure 4—figure
supplement 1A and B). Notably, this phenotype was not due to an altered drinking behavior of Tri-
aka animals (Figure 4—figure supplement 1C). In addition, Triaka mice were also more susceptible
to chronic DSS-induced colitis (Figure 4—figure supplement 1D).
To assess a possible functional consequence of the differential expression of proliferation-associ-
ated genes in Triaka versus WT cIECs, we applied an in vivo wound-healing model and followed the
repair of experimentally-induced intestinal lesions in the two groups of mice. In these settings, we
Figure 2 continued
were considered significant. Red and orange dots represent genes with differences in transcript isoforms generated by bona fide alternative splicing
(AS) events or by other mechanisms, respectively (n = 4 donor mice per group). (B) Panel showing the relative frequency of the different isoforms
identified as AS events in (A) for 36 transcription start sites and from 35 genes, in WT versus Triaka cIECs. (C) Transcript levels for the indicated isoforms
were measured in WT and Triaka cIECs using qPCR and normalized to Gapdh expression (n = 6–11 mice per group). Cd44v4-5: Cd44 variant 4–5. (D)
Immunohistochemistry was performed on colonic tissue of indicated mice to detect total CD44 (CD44t) or CD44v4. Representative pictures and
percentage of positive cells for the indicated staining intensities are shown (n = 5–6 mice per group, pooled from three independent experiments).
Histograms represent the mean ± standard error of the mean. Statistics: (C) Student’s t test; (D) Mann-Whitney test. *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001.
DOI: https://doi.org/10.7554/eLife.28366.005
The following source data and figure supplement are available for figure 2:
Source data 1. Altered ratios of transcript isoforms in Triaka epithelial cells.
DOI: https://doi.org/10.7554/eLife.28366.007
Figure supplement 1. CD44 expression in Triaka and WT colons.
DOI: https://doi.org/10.7554/eLife.28366.006
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Figure 3. Esrp1Triaka decreases the barrier function of the intestine. (A) Representative flow cytometry plot of colonic single cells stained for EpCAM
and CD45 (left panel). Representative histogram indicating surface E-cadherin expression on EpCAM+ epithelial cells (right panel). (B) Median
fluorescence intensity (MFI) of E-cadherin expression on EpCAM+ cells from WT and Triaka mice. Data from one representative experiment of three are
shown (n = 5 mice per group). (C) Intestinal barrier resistance in colonic tissue of WT and Triaka was measured using an Ussing chamber (n = 6 mice per
group, pooled from two independent experiments). (D) Immunofluorescence for 16S rRNA (in red) was performed on colon tissue. Nuclei were
visualized with DAPI. White arrows indicate presence of bacterial products in mucus and crypts of Triaka mice. Representative pictures are shown
(n = 7–8 mice per group). Scale bars: overview: 200 mm; detail: 100 mm. (E) Commensal-specific IgG1 and IgG2b antibodies were assessed in the serum
of WT and Triaka animals. Representative flow cytometry histograms are shown (n = 10 per group). Data are shown as mean ± standard error of the
mean. Statistics: (B) and (C) Student’s t test. **p<0.01; ****p<0.0001.
DOI: https://doi.org/10.7554/eLife.28366.008
The following source data and figure supplements are available for figure 3:
Source data 1. Gene expression and pathway analysis.
DOI: https://doi.org/10.7554/eLife.28366.012
Figure supplement 1. Esrp1Triaka alters the expression of genes associated with cell proliferation.
DOI: https://doi.org/10.7554/eLife.28366.009
Figure supplement 2. Normal colonic histomorphology in Triaka mice.
DOI: https://doi.org/10.7554/eLife.28366.010
Figure supplement 3. Normal small intestinal barrier integrity, fecal lipocalin-2 and albumin levels in Triaka mice.
DOI: https://doi.org/10.7554/eLife.28366.011
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observed diminished wound-healing in Triaka compared with WT mice (Figure 4C). In contrast to
what we observed at steady-state, these data imply that Esrp1Triaka impairs the proliferative or
regenerative capacity of cIECs during intestinal pathology.
Next, we tested whether the increased susceptibility to DSS-colitis and the lower repair ability of
Triaka mice may influence cell proliferation and pathogenesis in a CRC model. We found that in
azoxymethane (AOM) and DSS-treated Triaka mice, colorectal tumors were reduced in number and
size compared with WT controls, thus providing additional evidence for a defective proliferation of
Triaka IECs (Figure 4D and E). The tumor grade was not different between the two groups
(Figure 4F). However, molecular analysis revealed more pronounced upregulation of matrix metallo-
proteinase-3, granulocyte-colony stimulating factor, transforming growth factor b1 and interleukin-
1a in Triaka versus WT tumors (Figure 4—figure supplement 2). These proteins are all established
drivers of CRC progression, EMT and metastasis, thus indicating a more aggressive phenotype of
Triaka tumors (Li et al., 2016; Mroczko et al., 2006; Morris et al., 2014; Calon et al., 2012;
Matsuo et al., 2009). These features of Esrp1Triaka CRC lesions likely resulted from a partial EMT sig-
nature expressed by Triaka cIECs, prior to transformation (Figure 4—figure supplement 3).
To address the hypothesis that the above-observed phenotypes were indeed due to impaired
cIECs proliferation in Triaka mice, we last analyzed intestinal Ki-67 expression in the colonic mucosa,
after a 3 day treatment with DSS. Under these conditions of mild intestinal inflammation, which are
not sufficient to induce epithelial erosions, Triaka cIECs showed reduced Ki-67 expression compared
with WT cIECs (Figure 4G and H).
Taken together, these results indicate that altered Esrp1-regulated mRNA splicing deregulates
cIEC function and affects the development of intestinal disease in Triaka mice, through a mechanism
reducing IEC proliferation.
Esrp1Triaka regulates the Wnt pathway via Gpr137 isoforms
We next investigated the molecular mechanisms downstream of Esrp1Triaka that lead to diminished
proliferation of Triaka IECs. Among the 35 genes showing splicing isoforms with different relative
frequency in Triaka versus WT cIECs, we chose genes for which only two isoforms were differently
expressed. Of those, Gpr137 emerged as a prominent candidate since it is involved in IEC prolifera-
tion (Zhang et al., 2014), although the mode of action of this orphan G protein-coupled receptor
(GPCR) or of its isoforms is unknown. Thus, the two Gpr137 splicing isoforms with different relative
frequency in Triaka versus WT cIECs, Gpr137_ENSMUST00000166115 and Gpr137_EN-
SMUST00000099776 (referred hereafter as Gpr137_Long and Gpr137_Short, respectively), were
selected for further functional studies. By using our in vitro reporter system, we could validate that
Gpr137 is a splicing target of ESRP1 (Figure 5—figure supplement 1). Our RNA sequencing analysis
indicated that Gpr137_Long is preferentially expressed in Triaka cIECs, whereas Gpr137_Short is
predominant in WT cIECs. To address a potentially distinct role of Gpr137_Long versus
Gpr137_Short in cIECs, CMT-93 cells were transduced with lentiviral vectors encoding these two
Gpr137 isoforms. We found a decreased cell proliferation and diminished epithelial monolayer tight-
ness, as indicated by lower electrical resistance, in Gpr137_Long- versus Gpr137_Short-expressing
cells. Importantly, in this particular assay the barrier function appeared to be distinct from the IEC
proliferation. Indeed, although control vector-transduced cells proliferated less than cells transduced
with vectors encoding Gpr137 isoforms, they formed a tighter barrier (Figure 5A and B, Figure 5—
Table 1. Bacterial translocation and serum anti-commensal antibodies.
No. of WT mice No. of Triaka mice p-value
Penetration of bacteria in mucus or mucosa
16S rRNA 0/9 6/8 0.0023
Serum anti-commensal antibodies
IgG1 1/10 7/10 0.0198
IgG2b 1/10 8/10 0.0055
Statistics: Fisher’s exact test was performed. This table relates to Figure 3.
DOI: https://doi.org/10.7554/eLife.28366.013
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figure supplement 2A). These effects of the two Gpr137 isoforms on IEC proliferation and barrier
integrity were independent of their relative expression levels and of possible cytotoxic effects (Fig-
ure 5—figure supplement 2B and C). Transduction with Gpr137 isoforms also distinctively
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DOI: https://doi.org/10.7554/eLife.28366.014
The following figure supplements are available for figure 4:
Figure supplement 1. Triaka mice show increased susceptibility to experimental colitis.
DOI: https://doi.org/10.7554/eLife.28366.015
Figure supplement 2. More aggressive molecular signature in Triaka intestinal tumors.
DOI: https://doi.org/10.7554/eLife.28366.016
Figure supplement 3. Partial EMT signature in Triaka cIECs.
DOI: https://doi.org/10.7554/eLife.28366.017
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enhanced the proliferation of murine MC-38 and human Caco-2 IEC lines, thus validating our find-
ings in CMT-93 cells (Figure 5—figure supplement 2D and E).
To dissect the differential effect of the two Gpr137 isoforms on CMT-93 cells, we then investi-
gated the activation of signaling pathways known to regulate epithelial cell proliferation or barrier
function. Among the pathways examined, differences were only observed for Wnt/b-catenin signal-
ing. Indeed, we found a one-third reduction in levels of active b-catenin protein in Gpr137_Long-
versus Gpr137_Short-transduced cells (Figure 5C), which was validated in Esrp1Triaka- versus
Esrp1WT-transduced cells (Figure 5—figure supplement 3). Furthermore, pharmacological inhibition
of Wnt/b-catenin signaling abrogated the proliferative advantage of Gpr137_Short- over
Gpr137_Long-transduced cells (Figure 5D). This suggested that Gpr137 isoforms modify epithelial
function via regulation of Wnt/b-catenin signaling. In line with these in vitro data, we measured ca.
40% reduced levels of active b-catenin, as well as diminished expression of Wnt target genes
(Herbst et al., 2014) in cIECs of Triaka compared with WT mice (Figure 5E and F). Collectively,
these results show that distinct Gpr137 isoforms can differently modulate the Wnt/b-catenin pathway
and IEC function, which may partially underlie the intestinal phenotype of Triaka mice.
ESRP1 expression is reduced in the diseased human intestine
To address the general relevance of the findings from our in vitro and in vivo studies, we next
assessed ESRP1 expression in intestinal biopsies from Crohn’s disease (CD) patients, after normaliza-
tion to an epithelial-specific marker. Compared with non-inflamed paired biopsies, ESRP1 levels
were downregulated in the inflamed biopsies from CD intestines (Figure 6A). This correlated with
reduced nuclear ESRP1 expression in the inflamed CD intestine, as measured by high-throughput
automated immunohistochemistry quantification (Figure 6B).
We also performed a tissue microarray (TMA) based analysis of matched intestinal tissues from a
cohort of 185 CRC patients, which revealed a gradual decrease in nuclear expression of ESRP1 pro-
tein during cancer progression (Table 2). Furthermore, low nuclear ESRP1 expression was associated
with reduced patient survival (p=0.0456), larger tumors (p=0.0034), lymphatic invasion (p=0.0466),
advanced pT-stage (p=0.02) and presence of nodal metastasis (p=0.016) (Figure 6C and Figure 6—
source data 1). ESRP1 expression was determined to be an independent prognostic factor, after
adjusting for the confounding effects of pT, pN, pM, tumor budding, and lymphatic invasion (Fig-
ure 6—source data 2). This indicates a possible tumor-suppressive role of ESRP1 in CRC. Finally, we
analyzed in The Cancer Genome Atlas (TCGA) RNA sequencing data of intestinal tissue from CRC
patients to evaluate the relative frequency of GPR137 isoforms in the human intestine. We found a
positive correlation between the expression of ESRP1 and GPR137_ENST00000539833 (referred
hereafter as hGPR137_Short) in normal intestine tissue, which we further validated using indepen-
dent samples (Figure 6D and Figure 6—figure supplement 1A). Moreover, there was an associa-
tion between hGPR137_Short expression and transcript levels of Wnt target genes, suggesting a
similar signaling downstream of GPR137 in humans and mice (Figure 6—source data 3).
In human CRC, the ratio between hGPR137_Short and GPR137_ENST00000377702 (referred
hereafter as hGPR137_Long) isoforms was altered compared with normal intestinal tissue
(Figure 6E). Similarly, transcript levels of Gpr137_Long were increased in murine CRC tissue (Fig-
ure 6—figure supplement 1B). Importantly, a higher ratio of hGPR137_Short to hGPR137_Long
transcripts predicted enhanced CRC patient survival, thereby indicating a protective role of the
ESRP1-dependent hGPR137_Short isoform (Figure 6F). Indeed, higher expression levels of
hGPR137_Short alone was also associated with better prognosis (Figure 6—figure supplement 1C).
Figure 5 continued
The following figure supplements are available for figure 5:
Figure supplement 1. Gpr137 is a splicing target of ESRP1.
DOI: https://doi.org/10.7554/eLife.28366.019
Figure supplement 2. Gpr137 isoforms differently modulate the proliferation of epithelial cells.
DOI: https://doi.org/10.7554/eLife.28366.020
Figure supplement 3. Reduced Wnt/b-catenin signaling in Esrp1Triaka- compared with Esrp1WT-transduced cells.
DOI: https://doi.org/10.7554/eLife.28366.021
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Figure 6. Expression of ESRP1 and ESRP1-dependent hGPR137 isoforms is down-regulated in the diseased intestine and predicts CRC patient survival.
(A) ESRP1 transcript levels were measured in inflamed versus matched, non-inflamed intestinal biopsies from Crohn’s disease (CD) patients and
normalized to EPCAM expression. Normalized ESRP1 transcript levels in the non-inflamed biopsy were set to one for each patient and fold induction
was calculated for the corresponding inflamed biopsy (n = 15 samples per group). Data represent means ± standard error of the mean. (B)
Immunohistochemistry was performed on intestinal tissue of CD patients to detect nuclear ESRP1, which was measured using automated quantification
and normalized. Representative pictures are shown from a patient during remission and active disease, respectively (n = 31, 32, 7 and 14 biopsies per
indicated group of cases). Data represent means ± standard error of the mean. Scale bars: 50 mm. (C) Kaplan-Meier survival curves of CRC patients with
high (n = 77) or low (n = 88) expression of ESRP1 in tumor tissues. Representative IHC showing ESRP1-high and -low intestinal tumors. Scale bars: 100
mm. (D) Correlation between ESRP1 and hGPR137_Short expression in normal tissue of the large intestine (n = 51). (E) hGPR137_Short and
hGPR137_Long isoform expression in tumor (n = 647) versus normal (n = 51) tissue of the large intestine. Data represent means ± standard error of the
mean. (F) Kaplan-Meier survival curves of CRC patients with a high (n = 142) or low (n = 261) ratio of hGPR137_Short to hGPR137_Long transcripts in
tumor tissues. Statistics: (A) Wilcoxon signed-rank test, (B) One-way ANOVA with Bonferroni post-test, (C) and (F) Log-rank test, (D) Spearman
correlation, (E) Kruskal-Wallis with Dunn’s post-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
DOI: https://doi.org/10.7554/eLife.28366.022
The following source data and figure supplements are available for figure 6:
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These findings extend our in vivo data in Esrp1Triaka mice and substantiate their relevance for the
human intestine. They also suggest an involvement of hGPR137 isoforms in human CRC tumorigene-
sis and progression.
Collectively, our data in mice and humans indicate that downregulation or loss of ESRP1 function
results in dysregulation of alternative mRNA splicing in IECs. This leads to impaired epithelial cell
integrity and contributes to intestinal pathology, possibly via altered Gpr137/GPR137 isoform ratios
(Figure 6—figure supplement 2).
Discussion
Here, we describe a mouse model with hypomorphic ESRP1 function that shows impaired intestinal
epithelial barrier integrity. This was associated with changes in the relative frequency of distinct
mRNA isoforms in IECs and accompanied by an altered epithelial phenotype, as indicated by dimin-
ished surface E-cadherin expression. Of the 35 genes with splicing isoforms present at different
ratios in Triaka versus WT primary cIECs, we identified two isoforms of Gpr137 that differently
affected IEC function via modulation of the Wnt signaling pathway. In support of these data from
mouse models demonstrating a role for Esrp1 in intestinal integrity, ESRP1 was downregulated in
colonic tissue from CRC patients. Furthermore, the ratio of specific GPR137 isoforms varied in tumor
versus normal intestinal human samples, and expression of a specific ESRP1-dependent GPR137 iso-
form predicted CRC patient survival. Little is known about GPR137, an orphan GPCR whose knock-
down leads to reduced proliferation of several cancer cell lines, including colon cancer cells
(Zhang et al., 2014). In particular, the function of distinct Gpr137/GPR137 isoforms in IECs has not
been addressed so far. GPR137 is ubiquitously and abundantly expressed in mouse tissues and is
most closely related to OR51E2/PSGR, a prostate-specific GPCR (Vanti et al., 2003; Regard et al.,
2008).
Interestingly, recent data suggest that GPR137 may be involved in EMT. Indeed, silencing of
GPR137 resulted in a downregulation of SNAI1/SNAIL and SNAI2/SLUG and a corresponding
increase in E-cadherin expression in human prostate cancer cells (Ren et al., 2016). Gpr137_Short
and hGPR137_Short are predicted to encode a protein with five transmembrane domains, whereas
the products of Gpr137_Long and hGPR137_Long have a seven-transmembrane-spanning motif.
Human and mouse GPR137 proteins have a 78% identity, yet the respective short and long isoforms
Figure 6 continued
Source data 1. Association of (nuclear) ESRP1 expression with clinicopathological features in 185 CRC patients.
DOI: https://doi.org/10.7554/eLife.28366.025
Source data 2. Univariate and multivariate survival analysis in 185 CRC patients.
DOI: https://doi.org/10.7554/eLife.28366.026
Source data 3. Correlation of hGPR137_Short with Wnt target genes.
DOI: https://doi.org/10.7554/eLife.28366.027
Figure supplement 1. Expression of GPR137 isoforms in the healthy and diseased intestine.
DOI: https://doi.org/10.7554/eLife.28366.023
Figure supplement 2. ESRP1-dependent alternative mRNA splicing is required for epithelial integrity and intestinal homeostasis.
DOI: https://doi.org/10.7554/eLife.28366.024
Table 2. Gradual loss of nuclear ESRP1 expression is associated with CRC progression
Tissue type Number of cases ESRP1 expression (%) p-value
Average Median
Normal 26 75 75 <0.0001
Adenoma 42 56.8 60
Carcinoma 185 26.5 15
Lymph node metastasis 68 9.1 0
Statistics: Kruskal-Wallis test was performed. This table relates to Figure 6.
DOI: https://doi.org/10.7554/eLife.28366.028
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we report here do not directly match between the two species. The molecular mechanisms by which
distinct Gpr137/GPR137 isoforms differently regulate Wnt/b-catenin signaling or possibly determine
CRC survival have yet to be investigated.
Our data indicate a reduction of active b-catenin levels in primary Esrp1Triaka IECs and a subse-
quent downregulation of the transcription of some – but not all – Wnt target genes. Active b-catenin
was similarly decreased in CMT-93 cells transduced with an Esrp1Triaka- or a Gpr137_Long-express-
ing lentiviral vector, compared to controls. The Wnt/b-catenin pathway is central to maintain tissue
renewal and stem cell activity in IECs as well as epithelial cell proliferation in intestinal crypts.
Genetic ablation of b-catenin in adult mice leads to intestinal epithelial stem cell (IESC) differentia-
tion, thereby resulting in impaired intestinal homeostasis and fatal loss of intestinal function
(Fevr et al., 2007). Reduced Wnt/b-catenin signaling likely underlies the diminished healing capacity
of Triaka IECs and their reduced proliferation after transformation in the AOM/DSS model. In con-
trast, the Wnt/b-catenin pathway is aberrantly activated in most CRC, often caused by APC loss-of-
function (Clevers and Nusse, 2012). Therefore, our study suggests a link between ESRP1 and Wnt/
b-catenin signaling in the intestine.
Besides Gpr137, we also revealed other genes with altered splicing patterns in Triaka compared
with WT cIECs, which likely also contribute to the intestinal phenotype in Triaka mice. Among those
ESRP1 target genes, Cd44 is probably the most studied for its intestinal function. CD44 and its iso-
forms negatively regulate IEC apoptosis (Zeilstra et al., 2008; Lakshman et al., 2004) and partici-
pate in various cellular functions, such as proliferation, adhesion, and migration (Ponta et al., 2003).
Furthermore, CD44v4 and CD44v6 isoforms are overexpressed in neoplastic IECs of patients with
familial adenomatous polyposis (Zeilstra et al., 2014). The expression of Cd44v4 and Cd44v6 iso-
forms in murine IESCs positively correlates with expression of LGR5, a marker of adult IESCs, and
CD44 variant isoforms promote CRC in ApcMin/+ mice (Zeilstra et al., 2014). Therefore, the
decreased expression of CD44v4 protein in Esrp1Triaka IECs may likewise explain the reduced intesti-
nal tumorigenesis observed in Triaka compared with WT mice.
Although our data indicate reduced splicing activity from the Triaka mutation, a possible neomor-
phic effect of ESRP1Triaka cannot be fully excluded, and further investigation using other genetic
models is required to examine this aspect.
ESRP1 has also been reported to restrict pluripotency in embryonic stem cells (Fagoonee et al.,
2013), and it may as well regulate the differentiation of adult stem cells, including IESCs. Similarly,
ESRP1 downregulation promotes cancer cell stemness and metastasis (Preca et al., 2015). Accord-
ingly, frameshift mutations of ESRP1 are found in 25% of microsatellite instability-positive CRC
tumors (Ivanov et al., 2007). Furthermore, our results from a CRC cohort show that ESRP1 protein is
gradually downregulated during the adenoma to carcinoma sequence in intestinal tumors and that
few cells express it in lymph node metastases. These findings strengthen previous data suggesting a
tumor-suppressive role of ESRP1 in CRC cells (Leontieva and Ionov, 2009). Remarkably, ESRP1
appears to be involved early during CRC tumorigenesis, since it is already downregulated in ade-
noma. Reduction of ESRP1 function in adenomatous lesions may compromise the intestinal barrier,
thereby facilitating the penetration of bacterial products and promoting inflammation-mediated
CRC development (Grivennikov et al., 2012).
Our data in mice suggest that while AOM/DSS-induced Triaka tumors are smaller, they show a
more aggressive molecular signature. We do not have a definitive explanation for these seemingly
opposing results. However, ESRP1 is a key regulator of EMT – it maintains the epithelial phenotype
of a cell – and ESRP1 downregulation leads to a shift towards a mesenchymal phenotype. Indeed,
we find higher transcript levels of the EMT-promoting transcription factors Zeb1 and Zeb2 in Triaka
compared with WT cIECs. As EMT is associated with reduced proliferation as well as increased motil-
ity and invasiveness of malignant cells, this may account for the phenotype of Triaka tumors
(Kalluri and Weinberg, 2009; Evdokimova et al., 2009; Hur et al., 2013).
Although we investigated ESRP1 expression and not ESRP1 mutations in human CRC, our in vitro
data indicate a direct correlation between ESRP1 expression and splicing activity mediated by
ESRP1. Therefore, we believe that Triaka mice, characterized by decreased ESRP1 activity, represent
a valid model to address the contribution of Esrp1-dependent mRNA splicing to intestinal function.
In summary, our results demonstrate a role for Esrp1 in intestinal homeostasis and disease in
mice. Our findings also suggest that loss of ESRP1 may contribute to CRC and IBD development in
humans. Moreover, we identified GPR137 as a novel splicing target of ESRP1 and found that distinct
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isoforms of GPR137 regulate intestinal homeostasis by modulating IEC function through the Wnt/b-
catenin pathway. Additional studies investigating the role of GPR137 and ESRP1 in the intestinal epi-
thelium are warranted to understand how distinct GPR137 isoforms impact on CRC patient survival
and to reveal strategies to target the ESRP1-GPR137 axis.
Materials and methods
Patient selection
A multi-punch TMA of matched tumor, adenoma and normal tissue from 220 CRC well-characterized
patients surgically treated from 2004 to 2007 at the Aretaieion University Hospital, University of
Athens, Greece was used to evaluate changes in ESRP1 expression during tumor progression and
impact on clinicopathological features (see also Figure 6—source data 1). Additionally, RNAlater
(Thermo Fisher Scientific, Waltham, MA) -stored and formalin-fixed paraffin-embedded biopsies
from IBD patients were obtained from the Swiss IBD Cohort (http://www.ibdcohort.ch/) and from
the Institute of Pathology of the University of Bern (Switzerland), respectively. Alternatively, CRC tis-
sues were provided by the Tissue Bank Bern. The use of patient data and samples was approved by
the Ethics Committee at the University of Athens, Greece and the Cantonal Ethics Committee of
Bern.
Evaluation of ESRP1 in CRC and IBD cases
Nuclear ESRP1 expression in CRC tissue was detected by immunohistochemistry (IHC) and scored
by a pathologist (V.H.K.). In detail, each spot was evaluated for the percentage of epithelial cells
showing ESRP1 expression (0–100%). Additionally, the intensity of staining was evaluated on a four
point scale (0-3). Final scores were formed by multiplication of these two values (range 0–300) and
evaluated in correlation with clinicopathological features and survival. For the Kaplan-Meier curves,
Receiver Operating Characteristic curve analysis was performed to identify the optimal immunohisto-
chemical cut-off score with lymph node metastasis as the endpoint. Based on this analysis, a cutoff
value of 20% ESRP1 expression in tumors was chosen to separate ESRP1-high from -low tumors. Uni-
variate and multivariate survival analyses were carried out using Cox proportional hazards regres-
sion. All significant variables in univariate analysis were entered into multivariate analysis. Hazard
ratios and 95% CI were used to determine the effect size for the outcome overall survival.
Nuclear ESRP1 expression in intestinal epithelial cells (IECs) was quantified using Oncotopix Dis-
covery (RRID:SCR_015690; Visiopharm, Hoersholm, Denmark) and applying a custom-made algo-
rithm developed by the authors. In brief, inflammation grade was assessed for each biopsy on H&E-
stained tissue sections by a board-certified pathologist (V.G.), in a single-blinded manner, and classi-
fied into no, mild, moderate and severe inflammation. Sequential sections were then stained for
ESRP1 and analyzed.
The analysis algorithm was first designed to automatically distinguish IEC areas from stroma and
background. Nuclear ESRP1 expression in IECs was then stratified into no, low, moderate and high
expression and the area of these different intensity values was quantified for each biopsy. Thereaf-
ter, the area-corrected mean brown stain intensity value was calculated for each biopsy. Finally,
intensity values were normalized to mildly inflamed biopsies on each slide to control for potential
staining variability between slides.
Immunohistochemistry and immunofluorescence of human and mouse
tissue
IHC was performed on sections (2.5 mm) of IBD biopsies and on the TMA using the BondMax system
(Leica, Wetzlar, Germany) in Bond Epitope Retrieval Solution 2 (citrate, pH 9.0) for 60 min at 95˚C.
Tissues were then stained for ESRP1 (1:50, Thermo Fisher Scientific, Waltham, MA). The Bond Poly-
mer Refine Detection kit (Leica) was used for the detection of ESRP1-positive cells.
For IHC on formalin-fixed paraffin-embedded murine colon tissue, a heat-induced epitope
retrieval was first performed for 18 min in a steam cooker in 1 mM Tris/1 mM EDTA (pH 9.0). A pri-
mary antibody detecting total CD44 (1:100, rat anti-mouse, Becton Dickinson, Franklin Lakes, NJ),
CD44v4-containing isoforms (1:100, rat anti-mouse, eBioscience, Santa Clara, CA) or Ki-67 (1:200,
Dako, Santa Clara, CA) were then used. Specific binding of primary antibodies was visualized using a
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secondary antibody (1:200, goat anti-rat, Dako) followed by a tertiary antibody with linked horserad-
ish peroxidase (HRP) as the enzyme (EnVision+, anti-goat, Dako), and 3,3’-diaminobenzidine as the
chromogen. Staining intensity of positive cells was quantified using an automated scanner and soft-
ware (Aperio, Sausalito, CA).
Bacterial 16S rRNA was detected with the eubacterial probe EUB338 (5’-GCTGCCTCCCGTAG-
GAGT-3’) (Lu¨cker et al., 2007) labeled with Alexa647 (Eurofins). Sections were counterstained with
DAPI (1:2000, BioLegend, San Diego, CA) and placed in mounting medium (Dako). Fluorescence sig-
nal was detected using an Olympus IX81 confocal microscope combined with a FluoView FV1000
device (Olympus, Tokyo, Japan).
Animals
All animal experiments were performed in accordance with institutional and federal regulations gov-
erning animal care and use and were approved by The Scripps Research Institute (TSRI) Institutional
Animal Care and Use Committee (La Jolla, CA, USA) (IACUC protocols 07–0057 and 09–0079) and
the Cantonal Veterinary Office of Bern (Switzerland) (protocols BE76-11 and BE130/14). Animal
experiments were carried out in compliance with the ARRIVE reporting guidelines. All strains used
were on a C57BL/6 background. C57BL/6J mice (RRID:IMSR_JAX:000664) were purchased from
Jackson Laboratories and thereafter bred in-house. Esrp1Triaka mice (RRID:MGI:5515349) were gen-
erated at TSRI using N-ethyl-N-nitrosourea. For all experiments, non-randomized groups of 8–12
week old Esrp1Triaka/Triaka and C57BL/6J animals were either co-housed (for females) or soiled bed-
ding was exchanged weekly (for males) 3–4 weeks prior to and during experiments.
Identification of the Esrp1Triaka allele
The Esrp1Triaka allele was generated using N-ethyl-N-nitrosourea, as previously described
(Hoebe et al., 2003). It was initially identified to have a defect in natural killer cell (NK) cytotoxicity
as well as a hyperactivity and circling behavior. These phenotypes segregated in subsequent breed-
ing and the name Triaka was retained for the neurobehavioral phenotype. Initial confinement of the
mutation was made by outcrossing of Esrp1Triaka/Triaka mutation mice to C3H/HeN mice, followed by
backcrossing of F1 hybrids to the Esrp1Triaka/Triaka stock. The mutation was mapped to proximal
Chromosome 4, with a peak LOD of 2.71 at D4mit235. Fine mapping further defined a critical region
from the centromere to 13.7 mega base pairs. Whole genome sequencing of a homozygous Triaka
mouse using SOLiDTM (Thermo Fisher Scientific, Waltham, MA) revealed an A to G transition at posi-
tion 828 of Esrp1, for which 86.3%, 74.9%, and 62.3% of coding/splicing sequence was covered at
least 1, 2, or 3, respectively. Validation sequencing of the critical region covered all nucleotides
for which discrepancies were observed and confirmed the Esrp1Triaka mutation, which is located in
exon 4 of 16 total exons of Esrp1. The circling behavior, which is incompletely penetrant among
homozygous Triaka mice, was investigated in correlation with an auditory or neurodevelopmental
defect. However, Triaka mice displayed normal hearing in tests for auditory brain stem response and
distortion product otoacoustic emissions. In addition, there were no obvious abnormalities on histo-
logical sections of the neocortex, cerebellum, kidney, liver, lung, heart, pancreas, thymus and spleen.
Adult (8 to 12 week old) Esrp1Triaka were slightly leaner than WT mice (19 ± 1 g versus 21 ± 1 g for
females and 22 ± 2 g versus 26 ± 2 g for males, respectively), likely due to the hyperactive behavior.
Esrp1Triaka mice were later found to be susceptible to acute challenge with 2% dextran sodium sul-
fate (DSS). Increased susceptibility to DSS was also observed in homozygous versus WT mice on a
mixed C57BL/6J-C57BL/10J background. The Triaka strain is further described at the Southwestern
Medical Center Mutagenetix database (http://mutagenetix.utsouthwestern.edu) (Krebs et al.,
2016).
Evaluation of colonic crypt depth and goblet cells numbers
Colonic crypt depth was assessed in longitudinally-sectioned crypts on H&E-stained sections. Slides
were scanned and crypt depth was digitally measured in 20 crypts per mouse and averaged using
the Pannoramic Viewer software (RRID:SCR_014424; 3DHISTECH Ltd., Budapest, Hungary). Colonic
goblet cell numbers were assessed in longitudinally-sectioned crypts on PAS-stained sections using
the Pannoramic Viewer software. The number of PAS-positive cells per crypt was averaged from 10
crypts per mouse.
Mager et al. eLife 2017;6:e28366. DOI: https://doi.org/10.7554/eLife.28366 16 of 27
Research article Cancer Biology Cell Biology
Fecal albumin and lipocalin-2 measurement
Fecal pellets were collected, weighed and resuspended in PBS containing 1% FBS. A sandwich ELISA
for fecal albumin and lipocalin-2 was performed on 96-flat bottom Nunc MaxiSorp plates (eBio-
science). A purified anti-mouse albumin capture antibody (Bethyl Laboratories, Montgomery, TX)
and a secondary HRP-conjugated anti-mouse albumin antibody (Bethyl Laboratories) were used for
the capture and detection of fecal albumin. A Substrate Reagent Pack (R&D Systems, Minneapolis,
MN) was used for the color reaction and 1 M sulfuric acid was added to stop color development.
Colorimetric signals were measured on a SpectraMax M2e device (Bucher Biotec AG, Basel, Switzer-
land). Fecal lipocalin-2 was measured using the mouse Lipocalin-2/NGAL MAb ELISA kit (R&D sys-
tems), according to the manufacturer’s instructions.
Isolation and RNA sequencing of colonic intestinal cells
Colonic tissues were harvested and thoroughly washed in ice-cold calcium- and magnesium-free
Hank’s Balanced Salt Solution (HBSS). Colons were cut into 0.5–1 cm small pieces and digested in
pre-warmed calcium- and magnesium-free HBSS containing 25 mM HEPES (Sigma-Aldrich, St. Louis,
MO), 2 mM DTT (Sigma-Aldrich) and 5 mM EDTA (Merck, Darmstadt, Germany) at 37˚C for 20 min.
Supernatants were filtered through 70 mm cell strainers (BD Biosciences, San Jose, CA). The purity of
colonic IECs (cIECs) was assessed by flow cytometry and was generally 95% of cIECs (defined as
EpCAM+, CD45  cells) in Esrp1Triaka and WT mice. Frequencies of major immune cell populations
among CD45+ cells were analyzed in IEC preparations using the markers CD3, CD19 and CD11b
and were comparable in both groups of mice. Isolated cIECs were pelleted and suspended in TRI-
reagent (Sigma-Aldrich). For RNA sequencing, mRNA was purified and RNA concentration and
integrity were assessed using a Bioanalyzer 2100 (Agilent, Santa Clara, CA) prior to cDNA synthesis
and library preparation (TruSeq Stranded mRNA Sample Preparation, Illumina, San Diego, CA). The
libraries were sequenced on an Illumina HiSeq2500 sequencer by the Next Generation Sequencing
Platform of the University of Bern.
Computational analysis of RNA sequencing data
Between 45.7 and 59.1 million read pairs were obtained per sample. The reads were mapped to the
mouse reference genome (Ensembl m38, build 75) using TopHat v. 2.0.11 (RRID:SCR_013035)
(Kim et al., 2013). We then used HTseq-count v. 0.6.1 (RRID:SCR_011867) (Anders et al., 2015) to
count the number of reads per gene, and DESeq2 v. 1.4.5 (RRID:SCR_015687) (Love et al., 2014) to
test for differential expression between groups of samples. To investigate alternative pre-mRNA
splicing, we identified transcripts and quantified their expression levels as described in detail else-
where (Trapnell et al., 2012). Specifically, TopHat v. 2.0.11 (Kim et al., 2013) was used to map the
reads to the iGenomes reference (Ensembl NCBIM37 available from Illumina) for which an annotation
file with Cufflinks-specific attributes is available. For each sample taken separately, transcripts were
assembled with Cufflinks (RRID:SCR_014597) and then combined into a single assembly with Cuff-
merge (RRID:SCR_015688), resulting in approximately 145,000 transcripts. We tested for differential
expression between Esrp1Triaka and WT mice using Cuffdiff (RRID:SCR_001647) and visualized the
results with CummeRbund (RRID:SCR_014568). In particular, we identified genes where the relative
frequency of the isoforms from a given transcription start site (TSS) differed between Esrp1Triaka and
WT mice (false discovery rate (FDR)-adjusted p-value<0.05), consistent with alternative pre-
mRNA splicing.
Pathway analysis
The outcome of the DESeq2 analysis was taken to perform gene set enrichment analysis (GSEA)
using the SetRank method (RRID:SCR_015689) (Simillion et al., 2017). This algorithm first calculates
the p-value of a gene set utilizing the ranking of its genes in the ordered list of p-value as deter-
mined by DESeq2. Next, it discards gene sets that have been initially flagged as significant, if their
significance is merely due to the overlap with another gene set. Gene sets were derived from the fol-
lowing databases: REACTOME (RRID:SCR_003485) (Croft et al., 2014), Gene Ontology (RRID:SCR_
006447) (Ashburner et al., 2000), LIPID MAPS (RRID:SCR_006579) (Fahy et al., 2009), PhosphoSite-
Plus (RRID:SCR_001837) (Hornbeck et al., 2012), KEGG (RRID:SCR_012773) (Kanehisa et al., 2014),
BIOCYC (RRID:SCR_002298) (Karp et al., 2005), ITFP (RRID:SCR_008119) (Zheng et al., 2008) and
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WikiPathways (RRID:SCR_002134) (Kelder et al., 2012). Counts indicated in Figure 3—source data
1 were normalized for differences in total sequencing depth using size factor normalization in
DESeq2.
Measurement of intestinal barrier resistance
Intestinal barrier integrity was measured ex vivo using an Ussing chamber (Dipl.-Ing. K. Mussler, Sci-
entific Instruments, Aachen, Germany), as previously described (Clarke, 2009). In brief, colon tissue
was isolated from Triaka and WT mice, washed in ice-cold calcium- and magnesium-free HBSS and
then mounted in a 37˚C warm, oxygen saturated and HBSS-containing Ussing chamber. Electrical
resistance was measured after 10 to 15 min of equilibration time.
Measurement of serum anti-commensal antibodies
To assess systemic antibodies against intestinal commensals, fecal pellets were collected and intesti-
nal bacteria from pellets were cultured in brain-heart infusion medium for 24 hours. Autologous fecal
bacterial antibody binding was measured by bacterial flow cytometry. Complement in the serum
was heat-inactivated and serum was titrated on sodium azide-inactivated bacteria. Specific binding
of IgG1 and IgG2b to bacteria was detected with fluorochrome-labeled antibodies against mouse
IgG1 or IgG2b (BioLegend, San Diego, CA) on a FACSArray device (BD Biosciences).
Induction and assessment of colitis in mice
For the induction of acute colitis, animals were given 2% DSS (MP Biomedicals, Santa Ana, CA) in
the drinking water for 7 days, followed by regular water. For chronic colitis, DSS was given in 3
cycles with 5 days of DSS followed by 7 days of regular water. Animal weight was measured through-
out the procedure. Intestinal inflammation was assessed in a single blinded manner on H&E-stained
tissue sections by a board-certified pathologist (V.G.), as previously described (Brasseit et al.,
2016). Clinical disease activity was quantified as follows: Weight loss, compared to initial weight
(Score 0, <1% weight loss; score 1, 1–5% weight loss; score 2, 5–15% weight loss; score 4, 15–20%
or more weight loss); Stool consistency (Score 0, normal stool; score 2, loose stool; score 4, diar-
rhea); Intestinal bleeding (Score 0, negative; score 2, positive).
Colon wound-healing assay
Animals were anesthetized with isoflurane prior and during the experimental procedure. A miniature
flexible biopsy forceps was used to inflict 2–3 mucosal injuries per mouse. The procedure was visual-
ized using a miniature rigid endoscope system (Karl Storz, Tuttlingen, Germany). Wound-healing was
continuously monitored by colonoscopy 3, 4, 5, and 7 days after the biopsy. To quantify the surface
area of the excised mucosa and its subsequent regeneration, lesions were photographed and wound
areas were measured using Photoshop (RRID:SCR_014199; Adobe Systems, San Jose, CA) and nor-
malized to the forceps diameter.
Induction and assessment of intestinal tumors in mice
The azoxymethane (AOM) (Sigma-Aldrich)/DSS model of CRC was used to induce tumors, as previ-
ously described (De Robertis et al., 2011; Mertz et al., 2016). In short, mice were injected intraper-
itoneally (i.p.) with AOM (10 mg/kg of body weight). After 7 days, mice were given 1% DSS in the
drinking water for 5 days, followed by 7 days of regular water. Thereafter, animals received a second
injection of AOM, which was followed by two further cycles of DSS and regular water. Mice were
sacrificed 70 days after the first injection of AOM. Tumors were counted macroscopically and mea-
sured with a caliper by two independent observers. Tumor size was measured as previously
described (Neufert et al., 2007). A board-certified pathologist evaluated the tumor grade in a sin-
gle blinded manner. Grade was scored as follows: Grade 0: no tumor, healthy intestinal epithelium;
Grade 1: adenoma with mild dysplasia; Grade 2: adenoma with moderate dysplasia; Grade 3: ade-
noma with severe dysplasia; Grade 4: adenoma with high grade dysplasia and infiltration of the lam-
ina propria (carcinoma in situ); Grade 5: invasive carcinoma.
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Cytokine measurements
Tumors or adjacent tumor-free colonic tissue were suspended in RIPA buffer (Sigma-Aldrich, St.
Louis, MO) and homogenized using a TissueLyzer II (Qiagen, Venlo, Netherlands). Samples were
then centrifuged and the protein concentration in the supernatant was measured with a Bradford
Protein Assay (Bio-Rad, Hercules, CA). Protein concentrations were adjusted to 1500 mg/ml for each
sample. Cytokines were analyzed by Multiplexing LASER Bead Technology (Eve Technologies, Cal-
gary, Canada).
Flow cytometry
IECs or intraepithelial lymphocytes were filtered through a 70 mm cell strainer (BD Biosciences) to
obtain a single-cell suspension. Live/dead cell discrimination was performed using DAPI (BioLegend).
Intracellular staining was performed after fixation of cells with 4% paraformaldehyde for 5 min and
permeabilization with a 90% methanol solution at 4˚C for 30 min. Antibodies used for flow cytometry
are listed in Supplementary file 1.
Quantitative PCR analysis
RNA from isolated colonic IECs was extracted using TRI-reagent (Sigma-Aldrich). RNA was then
reverse-transcribed into cDNA using an M-MLV Reverse Transcriptase (Promega, Fitchburg, WI).
FastStart SYBR Green Master (Roche, Basel, Switzerland) and commercial primers specific for Cd44t,
Cd44v4/v5, Gapdh, Jun, Nedd9, Fgf18, ESRP1, and EPCAM (Qiagen, Venlo, Netherlands), as well as
self-designed primers for specific isoforms of Uap1, Magi1, and Gpr137 (Supplementary file 2)
were used for the qPCR reaction. Reactions were performed and analyzed on a StepOnePlus Real-
Time PCR System (Life Technologies, Carlsbad, CA). Unless indicated, transcript levels were normal-
ized to Gapdh expression. For tissue biopsies from Crohn’s disease patients, ESRP1 transcript levels
were normalized to GAPDH and EPCAM expression.
Generation of exon trap vector and in vitro assessment of splicing
activity
To generate a system to assess splicing events in vitro, an EcoRV restriction site was introduced into
a commercially-available exon trap vector (MoBiTec, Go¨ttingen, Germany) using the following pri-
mers: Fwd: 5’-GAGGCCCGATATCTTCAGACC-3’; Rev: 5’-GGTCTGAAGATATCGGGCCT-3’. A Fire-
fly luciferase gene (Promega) lacking the ATG start codon was then cloned into this EcoRV site. The
variable exon 5 of Cd44 along with parts of the flanking introns were amplified using the following
primers; Fwd: 5’-CGCGGGCTCGAGCATTGCAACAGATATAGAGACAGAATC-3’; Rev: 5’-
CGCGGGGCGGCCGCCCTCTTTCAGGCTCTGCAGA-3’. Similarly, a region of Fgfr2 containing exon
IIIb and IIIc, the intron in-between, as well as parts of the flanking introns were amplified using the
following primers; Fwd: 5’- CGCGGGCTCGAGGTCTGTTCTAGCACTACGGGGAT-3’; Rev: 5’-
CGCGGGGCGGCCGCGCAGTATGTACCTGGCGAAC-3’. For the cloning of the region of Gpr137
containing exons 2 and 3, we performed a first amplification using the following primers; Fwd: 5’-G
TGATGGGGTATCTCTGCTCC-3’; Rev: 5’-CCTTGATGTAGCACCCTTGGG-3’. This amplicon was
then used to perform a nested PCR reaction using the following primers; Fwd: 5’-CTCCCAGGTGG
TGTTCAATAGGCC-3’; Rev: 5’-CCAAGGTAGAGCCACC AACC-3’.
Amplicons were then cloned into the multiple cloning site of the modified exon trap vector. To
generate vectors encoding Triaka or WT Esrp1, cDNA of Esrp1WT and Esrp1Triaka were amplified
using the following primers: Fwd: 5’-CGCGGGGGATCCGCCACCATGACGGCGTCTCCGGATTA-3’;
Rev: 5’-CCCGCGGTCGACCTTAAATACAAACCCATTCTTTGGG-3’. Amplicons were then cloned
into a pBRIT-HA/FLAG vector (Addgene, Cambridge, MA). A third vector containing a Renilla lucifer-
ase gene was also used to control for variations in the transfection efficiency (Promega). HEK-293
cells (RRID:CVCL_0045) were transiently transfected by calcium phosphate co-precipitation with the
modified exon trap vector containing the cloned Cd44 or Fgfr2 regions, the Esrp1WT- or the Esrp1-
Triaka-encoding vector, and the Renilla luciferase-encoding vector. Firefly and Renilla luciferase activi-
ties were measured 24 hours after transfection in an Infinite 200 PRO reader (Tecan, Ma¨nnedorf,
Switzerland), using the Dual-Luciferase Reporter Assay (Promega). All cell lines were routinely tested
negative for mycoplasma contamination.
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Quantification of cell proliferation and epithelial monolayer resistance
CMT-93 cells (RRID:CVCL_1986) were cultured as recommended by ATCC. Cell proliferation was
either assessed by manual cell counting or using a WST-1 assay (Roche). In brief, 8  104 cells were
seeded into 6-well plates and cells were counted daily using a Neubauer chamber. Alternatively, 2–
8  103 cells were seeded into a 96-well plate and proliferation was measured using a WST-1 assay,
according to the manufacturer’s instructions.
To measure the trans-epithelial electrical resistance (TEER) of transduced CMT-93 cells, 4  104
cells were seeded onto rat tail collagen (Sigma Aldrich) coated 24-well plate ThinCertsTM inserts
(Greiner Bio-One, Kremsmu¨nster, Austria). These inserts were then placed into a cellZscope device
(nanoAnalytics, Mu¨nster, Germany) and TEER was measured every hour for up to 72 hours.
Construction and evaluation of tissue microarrays (TMAs)
Patient information on gender, age at diagnosis, tumor diameter, tumor location, post-operative
therapy and disease-specific survival time was extracted from clinical records. The UICC TNM Classi-
fication 7th edition was used to assess the T- (pT), N- (pN), and M-stage (pM), lymphatic invasion (L),
venous invasion (V), perineural invasion (Pn), tumor grade (G), histological subtype as well as tumor
growth pattern. For each case, two TMA spots (diameter 0.6 mm) each of tumor center and tumor
front and one spot of normal mucosa were stained for ESRP1 by immunohistochemistry (IHC). We
excluded 35 cases based on insufficient material remaining on the tissue block. Final number of
patients with invasive CRC was 185. From these patients, additional TMAs containing matched sam-
ples of normal colonic mucosa (n = 26), adjacent adenomas (n = 42) and lymph node metastases
(n = 68) were constructed. Patient characteristics are indicated in Figure 6—source data 1.
Lentiviral overexpression system
Lentiviruses encoding Gpr137_Long or Gpr137_Short were generated using HEK-293 cells as previ-
ously described (Tschan et al., 2003). In brief, HEK-293 cells were transfected with pMD2G,
pMDLg/pRRE, pRSV-Rev and pLV (Cyagen Biosciences, Santa Clara, CA) encoding EGFP with either
Gpr137_Long, Gpr137_Short, or a control sequence. HEK-293 cells were authenticated by short tan-
dem repeat (STR) profiling and confirmed to be mycoplasma-negative monthly. Lentiviruses were
then harvested to infect CMT-93 cells. Transduced CMT-93 cells were sort-purified based on EGFP
expression and kept under selection pressure using 5 mg/ml Puromycin (Sigma-Aldrich). CMT-93 cells
were originally purchased from the European Collection of Cell Cultures (ECACC no. 89111413) and
confirmed to be mycoplasma-negative monthly.
A 4-hydroxytamoxifen inducible system previously described elsewhere (Vince et al., 2007;
Wang et al., 2006) was modified to overexpress Esrp1Triaka, Esrp1WT or EGFP. To this aim, we
exchanged the Hoxb8 cassette of the original vector with cDNA of Esrp1Triaka or Esrp1WT. CMT-93
cells were then co-transduced with lentiviral vectors containing these different inserts and a lentiviral
vector encoding a 4-hydroxytamoxifen responsive element. Co-transduced cells were kept under
selective pressure using 5 mg/ml Puromycin and 200 mg/ml Hygromycin-B (Sigma-Aldrich). Expres-
sion of Esrp1Triaka, Esrp1WT or EGFP was induced with 100 nM 4-hydroxytamoxifen.
Data availability
RNA sequencing data form Triaka and WT IECs can be downloaded from the European Nucleotide
Archive (ENA) (http://www.ebi.ac.uk/ena/data/search?query=PRJEB14221). All RNASeqV2 data for
datasets COAD and READ (Cancer Genome Atlas Network, 2012) where downloaded though the
TCGA data portal (COAD: tumor: n = 480; normal tissue: n = 41. READ: tumor: n = 167; normal tis-
sue: n = 10) (https://tcga-data.nci.nih.gov/docs/publications/coadread_2012/; RRID:SCR_003193).
From the RSEM results Tables, we extracted gene expression levels for ESRP1, for all eight reported
GPR137 isoforms, for Wnt target genes specific for CRC (Herbst et al., 2014), as well as survival
data. All results are shown as transcripts per million obtained by multiplying the provided scaled
estimates by 106. The sequences of all GPR137 isoforms were obtained from the FASTA file in the
GAF bundle (hg19, June 2011).
For analysis of the survival data from the TCGA dataset, the X-tile software (RRID:SCR_005602)
(Camp et al., 2004) was used to separate GPR137_Short-high from -low tumors. CRC Patients with-
out survival data or with undetectable gene expression were excluded from the survival analysis.
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Statistical analysis
Sample size for in vivo studies was estimated by power analysis and adjusted for b = 0.1, with the
assumption that differences between the groups were 1.5–2 fold. Statistical tests are two-sided and
indicated in the figure legends. All statistical tests were performed with GraphPad Prism v.5.04 for
Windows (RRID:SCR_002798; GraphPad Software, La Jolla, CA). Statistical tests were chosen based
on the variation in each data group and on whether multiple comparisons were made. Groups with
similar variance were compared using parametric tests, and groups with significantly different varia-
tions were analyzed using non-parametric tests. No mouse was excluded from the analysis. Only sta-
tistically significant differences are indicated in the figures. For all statistical analyses: *p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001.
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